Description

Monalisa Ultra with Lidocaine

Monalisa Ultra is a professional injectable dermal filler formulated with cross-linked hyaluronic acid and lidocaine. It is the firmest formulation in the Monalisa Lidocaine collection, designed for professional treatments requiring substantial support and volume in suitable facial areas.

Each prefilled syringe contains 1ml of transparent hyaluronic acid gel formulated with 24mg/ml of cross-linked hyaluronic acid and 0.3% lidocaine. The incorporated lidocaine is intended to help improve patient comfort during administration.

Monalisa Ultra is manufactured in South Korea by Genoss Co., Ltd. It is intended exclusively for administration by appropriately qualified, trained and insured healthcare or aesthetic professionals.

What Is Monalisa Ultra Used For?

Monalisa Ultra is designed for professional facial contouring and volume restoration in suitable areas. Manufacturer product information identifies this formulation for deep-to-very-deep placement within the subcutaneous tissue, following an individual clinical assessment.

Published Monalisa information associates the Ultra formulation with suitable chin and facial-oval contouring applications, as well as selected nasal augmentation procedures. Product selection, treatment area, placement depth, quantity and technique must always be determined by the treating professional.

Not every patient, facial area or aesthetic concern is suitable for this product. A complete consultation, medical-history review and assessment of facial anatomy are essential before treatment.

Monalisa Ultra Product Specifications

• Product: Monalisa Ultra with Lidocaine
• Product type: Injectable hyaluronic acid dermal filler
• Syringe volume: 1ml
• Hyaluronic acid concentration: 24mg/ml
• Lidocaine concentration: 0.3%
• Particle size: Approximately 900 micrometres
• Recommended placement: Deep-to-very-deep subcutaneous tissue
• Listed needle sizes: 25G and 27G thin-wall needles
• Manufacturer: Genoss Co., Ltd.
• Country of manufacture: South Korea
• Storage: 2°C to 25°C
• Use: Qualified professional use only

Needle sizes and packaging contents may vary between markets. Always check the physical carton, product leaflet and supplied accessories before use or publication.

Key Features of Monalisa Ultra

• Firm cross-linked hyaluronic acid dermal filler
• Contains 24mg/ml hyaluronic acid and 0.3% lidocaine
• Approximately 900-micrometre particle profile
• Designed for suitable deep-volume and contouring applications
• Supplied in a sterile, ready-to-use 1ml prefilled syringe
• Manufactured using Monalisa Hy-BRID technology
• Intended for controlled administration by trained professionals
• Professional-use product only

Cross-Linked Hyaluronic Acid Technology

Hyaluronic acid is naturally found within the human body and supports tissue hydration and structure. In dermal fillers, cross-linking forms a gel that can provide temporary physical support and volume when correctly placed by a qualified practitioner.

According to the manufacturer, Monalisa products are made using Hy-BRID technology, a process designed to create dense and uniform hyaluronic acid particles. Monalisa Ultra has the largest particle profile in the collection, distinguishing it from the softer Soft, Mild and Hard formulations.

The product is biodegradable and is not a permanent implant. Any visible outcome and duration can vary according to placement, treatment area, product quantity, metabolism, lifestyle and individual patient factors. No outcome or duration can be guaranteed.

Monalisa Ultra Compared with Other Monalisa Fillers

• Monalisa Soft: Approximately 200-micrometre particles for superficial placement.
• Monalisa Mild: Approximately 400-micrometre particles for superficial or intermediate placement.
• Monalisa Hard: Approximately 600-micrometre particles for middle-to-deep placement.
• Monalisa Ultra: Approximately 900-micrometre particles for deep-to-very-deep placement.

Monalisa Ultra is the most robust option in this range. It should be selected only where a qualified practitioner considers its gel characteristics and intended depth appropriate. It is not interchangeable with a softer filler simply because a patient wants a more pronounced result.

Professional Consultation and Treatment Planning

A detailed consultation must take place before using Monalisa Ultra. The practitioner should assess the patient’s medical history, allergies, medications, previous aesthetic treatments, skin condition, anatomical considerations and treatment expectations.

The patient should receive clear information about the proposed treatment, realistic limitations, possible reactions, aftercare and alternative options. Informed consent must be obtained before administration. Product traceability information, batch number and expiry date should be recorded in the patient’s treatment notes.

Important Safety Information

Monalisa Ultra must never be injected into a blood vessel. Accidental intravascular administration of any dermal filler can cause serious complications, including vascular occlusion, tissue damage, skin necrosis, visual impairment, blindness or stroke.

Treatment requires detailed facial-anatomy knowledge, aseptic technique and the ability to recognise and manage complications without delay. Practitioners should have appropriate emergency procedures, equipment and referral arrangements in place.

Do not use Monalisa Ultra in patients with known hypersensitivity to hyaluronic acid, lidocaine, amide-type local anaesthetics or any other product component. Do not treat areas with active infection, inflammation, irritation, broken skin, untreated skin disease or an active cold-sore outbreak.

Pregnancy, breastfeeding, bleeding disorders, anticoagulant medication, immune conditions, severe allergies, recent procedures in the same area and a history of problematic scarring require careful professional assessment. Review the complete manufacturer’s instructions before use.

Possible Reactions and Aftercare

Temporary injection-site reactions may include redness, swelling, tenderness, bruising, itching, firmness, discomfort or discolouration. Less common complications can be serious and may require urgent intervention.

Patients should receive written aftercare guidance and clear instructions for contacting their practitioner. Unexpected or increasing pain, blanching, unusual skin colour, visual symptoms or neurological symptoms require immediate professional assessment.

Storage and Handling

Store Monalisa Ultra between 2°C and 25°C unless the carton supplied with your product states otherwise. Do not freeze the product or expose it to excessive heat.

Check the sterile packaging, syringe, gel appearance, expiry date and batch information before use. Do not use if the packaging is damaged, the product has expired or the gel appears abnormal.

The syringe and supplied needles are single-use devices. They must not be reused or resterilised. Dispose of all used equipment and unused product as appropriate clinical and sharps waste.

Order Monalisa Ultra

Monalisa Ultra with Lidocaine is available from The Clinic Vault for eligible professional purchasers. Customers are responsible for ensuring they have the qualifications, insurance, training and legal authority required to purchase and administer injectable aesthetic products.

Explore our professional aesthetic product collection or visit the Genoss instructions-for-use library for manufacturer documentation.

Professional-use notice: This page provides general product information. It does not replace the product instructions, accredited clinical training, local regulations, professional judgement or an individual patient assessment.